{
    "clinical_study": {
        "@rank": "89026", 
        "arm_group": [
            {
                "arm_group_label": "Acupuncture", 
                "arm_group_type": "Experimental", 
                "description": "Acupuncture treatment"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "No other active treatment or sham acupuncture for this symptoms"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether acupuncture can be effective for\n      chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients."
        }, 
        "brief_title": "Acupuncture for Chemotherapy-induced Peripheral Neuropathy", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Neuropathy", 
            "Toxicity Due to Chemotherapy", 
            "Lymphoma", 
            "Multiple Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Peripheral Nervous System Diseases", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age and have diagnosis of a lymphoma or multiple myeloma.\n\n          -  Patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2\n             according to CTCAE (Common Terminology Criteria for Adverse Events) v 3.0 scale\n             (Appendix A) in spite of previous conventional medications, e.g. Neurontin, Cymbalta\n             and/or Lyrica. Patients receiving any of conventional medication for this symptoms\n             must remain on the same medications throughout the study period.\n\n          -  Patients, or the legal guardians of patients, must have the ability to understand\n             Korean, and be ble to provide informed consent.\n\n          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, or 2.\n\n          -  If the patient is a woman of child-bearing potential, she must have a negative urine\n             pregnancy test and agree to use contraception.\n\n        Exclusion Criteria:\n\n          -  Other diseases that, in the opinion of the investigators, can cause peripheral\n             neuropathy, such as alcoholism, diabetes mellitus, and HIV.\n\n          -  Current active treatment for lymphoma or multiple myeloma\n\n          -  Ongoing local infection at or near the acupuncture point adopted in this trial.\n\n          -  Severe immunocompromised patients, leukopenia ( \uff1c 4,000/\u33a3) or neutropenia ( \uff1c\n             1,500/\u33a3)\n\n          -  Known coagulopathy, thrombocytopenia (\uff1c 50,000/\u33a3), and taking heparin (including low\n             molecular weight heparin) or Coumadin at any dose.\n\n          -  Serious emotional or mental problems that precludes study entry.\n\n          -  Mental and physical disability that precludes accurate acupuncture.\n\n          -  Serious systemic diseases such as active infection, severe heart disease,\n             uncontrolled hypertension and diabetes mellitus.\n\n          -  Cardiac pacemaker.\n\n          -  Pregnant or breastfeeding\n\n          -  Acupuncture therapy within the previous 30 days\n\n          -  Concurrent other complementary and alternative therapy such as herbal agents, high\n             dose vitamins, and etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892852", 
            "org_study_id": "AcuCIPN"
        }, 
        "intervention": {
            "arm_group_label": "Acupuncture", 
            "description": "Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.", 
            "intervention_name": "Acupuncture", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acupuncture", 
            "Traditional Korean Medicine"
        ], 
        "lastchanged_date": "July 16, 2013", 
        "location": {
            "contact": {
                "email": "yeast10@hanmail.net", 
                "last_name": "Chang Woo Han, PhD", 
                "phone": "+82-51-240-6835"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "602-739"
                }, 
                "name": "Department of Hematology-Oncology and Center for Integrative Medicine, Pusan National University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Ho-Jin Shin, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Chang Woo Han, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eui-Hyoung Hwang, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study", 
        "overall_contact": {
            "email": "yeast10@hanmail.net", 
            "last_name": "Chang Woo Han, PhD", 
            "phone": "+82-51-240-6835"
        }, 
        "overall_official": {
            "affiliation": "Pusan National University Hospital", 
            "last_name": "Ho-Jin Shin, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of NCIC-CTC (National Cancer Institute of Canada - Common Toxicity Criteria) 4.0 scale from baseline", 
            "safety_issue": "No", 
            "time_frame": "At baseline, 1, 2, 3, and 7 wks from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of VAS (Visual Analogue Scale) from baseline", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 1, 2, 3, and 7 wks from baseline"
            }, 
            {
                "measure": "Change of FACT/GOG-Ntx (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity) from baseline", 
                "safety_issue": "No", 
                "time_frame": "At baseline, 1, 2, 3, and 7 wks from baseline"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From study enrollment to the last follow-up (up to 7 wks)"
            }
        ], 
        "source": "Pusan National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pusan National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}